No Data
No Data
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn's and Colitis Congress
Stocks Mostly Rise Pre-Bell Ahead of Key Jobs Data; Asia, Europe Strong
Express News | Shattuck Labs Says As Of September 30, 2024, Cash And Cash Equivalents And Investments Were Approximately $90.1M That Is Expected To Fund Its Planned Operations Into 2027, Beyond Results From Its Phase 1 Trial Of SL-325
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
Shattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs Focuses on Promising Antibody Development
Unlock the Full List